Cite
Keogh RH, Cosgriff R, Andrinopoulou ER, et al. Projecting the impact of triple CFTR modulator therapy on intravenous antibiotic requirements in cystic fibrosis using patient registry data combined with treatment effects from randomised trials. Thorax. 2021;doi: 10.1136/thoraxjnl-2020-216265.
Keogh, R. H., Cosgriff, R., Andrinopoulou, E. R., Brownlee, K. G., Carr, S. B., Diaz-Ordaz, K., Granger, E., Jewell, N. P., Lewin, A., Leyrat, C., Schlüter, D. K., van Smeden, M., Szczesniak, R. D., & Connett, G. J. (2021). Projecting the impact of triple CFTR modulator therapy on intravenous antibiotic requirements in cystic fibrosis using patient registry data combined with treatment effects from randomised trials. Thorax, . https://doi.org/10.1136/thoraxjnl-2020-216265
Keogh, Ruth H, et al. "Projecting the impact of triple CFTR modulator therapy on intravenous antibiotic requirements in cystic fibrosis using patient registry data combined with treatment effects from randomised trials." Thorax vol. (2021). doi: https://doi.org/10.1136/thoraxjnl-2020-216265
Keogh RH, Cosgriff R, Andrinopoulou ER, Brownlee KG, Carr SB, Diaz-Ordaz K, Granger E, Jewell NP, Lewin A, Leyrat C, Schlüter DK, van Smeden M, Szczesniak RD, Connett GJ. Projecting the impact of triple CFTR modulator therapy on intravenous antibiotic requirements in cystic fibrosis using patient registry data combined with treatment effects from randomised trials. Thorax. 2021 Sep 23; doi: 10.1136/thoraxjnl-2020-216265. Epub 2021 Sep 23. PMID: 34556554.
Copy
Download .nbib